Source author record

Meinhard Kieser

Meinhard Kieser appears in the imported research catalog. Authorship, coauthor and topic links are available while profile ownership is still unclaimed.

ResearcherUnclaimed source record

Methodology Applications

Catalog footprint

What is connected

4works

2topics

4close collaborators

Actions

Connect this record

Open graph Browse works

Inspect adjacent papers, topics, institutions and collaborators without losing the researcher page.

Building this map preview

BZPEER is loading the nearby papers, people, topics and institutions for this page.

preprint2022arXiv

Analysis and sample size calculation within the responder stratified exponential survival model

The primary endpoint in oncology is usually overall survival, where differences between therapies may only be observable after many years. To avoid withholding of a promising therapy, preliminary approval based on a surrogate endpoint is possible. The approval can be confirmed later by assessing overall survival within the same study. In these trials, the correlation between surrogate endpoint and overall survival has to be taken into account for sample size calculation and analysis. For a binary surrogate endpoint, this relation can be modeled by means of the responder stratified exponential survival (RSES) model proposed by Xia, Cui, and Yang (2014). We derive properties of the model and confidence intervals based on Maximum Likelihood estimators. Furthermore, we present an approximate and an exact test for survival difference. Type I error rate, power, and required sample size for both newly developed tests are determined exactly. These characteristics are compared to those of the logrank test. We show that the exact test performs best. The power of the logrank test is considerably lower in some situations. We conclude that the logrank test should not be used within the RSES model. The proposed method for sample size calculation works well. The interpretability of our proposed methods is discussed.

preprint2020arXiv

Enhancing single-arm phase II trials by inclusion of matched control patients

When a novel treatment has successfully passed phase I, different options to design subsequent phase II trials are available. One approach is a single-arm trial, comparing the response rate in the intervention group against a fixed proportion. Another alternative is to conduct a randomized phase II trial, comparing the new treatment with placebo or the current standard. A significant problem arises in both approaches when the investigated patient population is very heterogeneous regarding prognostic factors. For the situation that a substantial dataset of historical controls exists, we propose an approach to enhance the classic single-arm trial design by including matched control patients. The outcome of the observed study population can be adjusted based on the matched controls with a comparable distribution of known confounders. We propose an adaptive two-stage design with the options of early stopping for futility and recalculation of the sample size taking the matching rate, number of matching partners, and observed treatment effect into account. The performance of the proposed design in terms of type I error rate, power, and expected sample size is investigated via simulation studies based on a hypothetical phase II trial investigating a novel therapy for patients with acute myeloid leukemia.

preprint2018arXiv

Sample size calculation and blinded recalculation for analysis of covariance models with multiple random covariates

When testing for superiority in a parallel-group setting with a continuous outcome, adjusting for covariates (e.g., baseline measurements) is usually recommended, in order to reduce bias and increase power. For this purpose, the analysis of covariance (ANCOVA) is frequently used, and recently, several exact and approximate sample size calculation procedures have been proposed. However, in case of multiple covariates, the planning might pose some practical challenges and surprising pitfalls, which have not been recognized so far. Moreover, since a considerable number of parameters have to be specified in advance, the risk of making erroneous initial assumptions, leading to substantially over- or underpowered studies, is increased. Therefore, we propose a method, which allows for re-estimating the sample size at a prespecified time point during the course of the trial. Extensive simulations for a broad range of settings, including unbalanced designs, confirm that the proposed method provides reliable results in many practically relevant situations. An advantage of the reassessment procedure is that it does not require unblinding of the data. In order to facilitate the application of the proposed method, we provide some R code and discuss a real-life data example.

preprint2016arXiv

Optimal adaptive two-stage designs for single-arm trial with binary endpoint

Minimizing the number of patients exposed to potentially harmful drugs in early onco logical trials is a major concern during planning. Adaptive designs account for the inherent uncertainty about the true effect size by determining the final sample size within an ongoing trial after an interim look at the data. We formulate the problem of finding adaptive designs which minimize expected sample size under the null hypothesis for single-arm trials with binary outcome as an integer linear program. This representation can be used to identify optimal adaptive designs which improve previous designs in two ways: Firstly, designs can be found exhibiting lower expected sample size under the null hypothesis than those provided by previous algorithms. Secondly, we explain how integer programming techniques can be exploited to remove pathologies of the optimal and previous solutions arising from the discrete nature of the underlying statistics. The resulting designs are both efficient in terms of expected sample size under the null hypothesis and well interpretable.